Biotech stocks are on the radar of a lot of investors, and for obvious reasons. With the pandemic at the forefront of everything, Biotech companies have been on a constant hunt for making vaccines & drugs to cure the virus. In light of the current situation, these four biotech companies are worth looking at. Investors must start shopping for these biotech stocks.
Are you planning to buy biotech stocks in June? This year, they have been quite in demand. Investors considering buying biotech stocks must understand the portfolio growth prospect in the sector and where they can find the highest growth potential. We know that with a considerable number of biotech stocks to choose from - investors might feel overwhelmed. This article will help with the top four biotechnology stocks which have been almost resilient through these tough times and are indeed going to reign for quite some time.
Investors have been watching all the clinical trials, new drugs & treatments since the pandemic. Some enjoy the risks involved in the biotechnology stocks investment. In the last few months, massive acquisitions have been taking place in the industry by some key players. That said, we understand that investors are closely watching the situation. So, if you are planning to invest in biotechnology stocks, keep your eyes open.
You Might Also be Interested in: Three Important Things to Keep in Mind When Investing in Biotechnology Stocks
Investing in biotech stocks might be riskier, but it can also be equally rewarding. And you will never know when that happens. Even a single drug has the potential to skyrocket the business and bring incredible results within a day. But, you have to be cautious, research and get your facts right at all times. So, if you are looking out to invest in biotechnology stocks, we’ve brought you some solid picks. Take a look:
You must keep in mind— the investment potential for biotechnology stocks might have improved due to the pandemic outbreak, but it is going to remain and is not limited to it. The spotlight that the vaccine development spree brought will remain. So let’s see which biotechnology stocks will bring you desired results.
It was long ago when GT Biopharma Inc. was trading below $5 a share. Right now, the Wall Street research analysts believe investors can buy GT Biopharma Inc. stocks with confidence. The biopharmaceutical company produces and sells immuno-oncology therapeutic products and is perfect for those looking to invest in biotechnology stocks at the moment. It is no longer penny stocks, and indeed, it was not back then when it started. It has now grown itself to something that can bring bullish interest from both analysts and traders. The company recently received a confirmation saying that it would be listed on the Russell 2000® Index at the end of June. So, if you are interested in trading on biotechnology stocks anytime soon, GT Biopharma Inc. stocks can be one of the best picks.
You Might Also be Interested in: Investing in Biotechnology Stocks? Here's What You Must Know!
Do you think it’s a great idea to buy the Avid Bioservices stocks at the moment? According to the latest data, the Avid Bioservices Inc stocks have already skyrocketed to 4.46% and have a bullish rating. Avid Bioservices is a manufacturing & contract development firm. The comprehensive range of its services includes top-notch commercial manufacturing & clinical services that it provides to the biotechnology industry. Avid Bioservices operates a commercial manufacturing space of 158,000 square feet. Until now, it has produced more than 150 commercial batches and markets its products in more than 90 countries. In the last five years, the Avid Bioservices stock prices have risen to a whopping 633%, which looks like a massive return for the long-term investors. So if you are looking to buy biotechnology stocks and make some meaningful wealth — Avid Bioservices is one option you should consider.
VBI Vaccines Inc. is developing and selling vaccines to treat different infectious diseases, including coronavirus, cytomegalovirus, and hepatitis B. The company is headquartered in Cambridge, Massachusetts. Through direct sales, it mainly serves pharmacists and physicians. In March this year, VBIV partnered with CEPI to develop vaccine candidates against SARS-CoV-2 variants. CEPI will provide the $33 million support through the first phase of its clinical development in the partnership.
The VBI Vaccines’ revenue was $301,000 for Q1, ending March 31. This figure indicates an increase of about 550.5% as compared to the fourth quarter of 2020. As of March 31, 2021, the company has a cash equivalent of $133.6 million. Analysts are predicting revenue of $472,000 for the company in this quarter. VBIV has added a valuation of 28.5% as compared to the last year & 22.6% through the past month. Analysts are expecting an increase in the VBI Vaccines Inc. stock prices by 106.3%. They also believe it could be a lucrative deal to invest in the stocks.
Over the past few months, Johnson & Johnson, the Blue-chip pharmaceutical company, is enjoying a successful phase altogether. After developing the COVID-19 vaccine and planning the launch of some exciting products— the company’s future undoubtedly looks brighter. According to recent data, the company has sold over 6.8 million doses of the Janssen vaccine, which has been administered throughout the US. So, for JNJ, the year has brought some favorable trends, and it looks like the company will remain there for long. And, the positive thing about JNJ is that it is one of the least volatile biotechnology stocks in the market today.
Johnson & Johnson is a well-positioned leading pharmaceutical company in producing and selling consumer health care products and medical devices. So, if you plan to invest in biotechnology stocks, JNJ would be one of the most bankable options for you. With many excellent prospects, it has some 14 novel drug launches in the pipeline by the end of 2023. And, the company’s persistent dividends are indicative of the JNJ stocks being one of the Best Biotech Stocks to Buy Right Now. Currently, the stock offers a 2.57% dividend yield.
We crave to hear happy stories from investors! And, we believe investing in the above four biotechnology stocks can bring us one.
More Valuable Reads from stockprices: